top of page

Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the Treatment of MM

  • Writer: Nammi Therapeutics
    Nammi Therapeutics
  • Jun 13, 2022
  • 1 min read

FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of multiple myeloma. QXL 138AM is a Masked Immunocytokine targeting a masked interferon alpha to the CD138 receptor on the surface of tumor cells.


 
 
 

Recent Posts

See All

Commentaires


©2019 Nammi Therapeutics, Inc.

bottom of page